Trial Profile
A Phase 1 Safety Study of LY2787106 in Patients with Cancer and Anemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs LY 2787106 (Primary)
- Indications Anaemia; Cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 21 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology